BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 20306040)

  • 1. 18F-FDG versus 11C-choline PET/CT for the imaging of advanced head and neck cancer after combined intra-arterial chemotherapy and radiotherapy: the time period during which PET/CT can reliably detect non-recurrence.
    Ito K; Yokoyama J; Kubota K; Morooka M; Shiibashi M; Matsuda H
    Eur J Nucl Med Mol Imaging; 2010 Jul; 37(7):1318-27. PubMed ID: 20306040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of 18F-FDG and 11C-choline PET/CT for detecting recurrences in patients with nonsquamous cell head and neck malignancies.
    Ito K; Yokoyama J; Kubota K; Morooka M
    Nucl Med Commun; 2010 Nov; 31(11):931-7. PubMed ID: 20827227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FDG-PET delayed imaging for the detection of head and neck cancer recurrence after radio-chemotherapy: comparison with MRI/CT.
    Kubota K; Yokoyama J; Yamaguchi K; Ono S; Qureshy A; Itoh M; Fukuda H
    Eur J Nucl Med Mol Imaging; 2004 Apr; 31(4):590-5. PubMed ID: 14722678
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective comparison of 18F-FDG PET with conventional imaging modalities (MRI, CT, and 67Ga scintigraphy) in assessment of combined intraarterial chemotherapy and radiotherapy for head and neck carcinoma.
    Kitagawa Y; Nishizawa S; Sano K; Ogasawara T; Nakamura M; Sadato N; Yoshida M; Yonekura Y
    J Nucl Med; 2003 Feb; 44(2):198-206. PubMed ID: 12571209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does 18F-FDG PET/CT improve the detection of posttreatment recurrence of head and neck squamous cell carcinoma in patients negative for disease on clinical follow-up?
    Abgral R; Querellou S; Potard G; Le Roux PY; Le Duc-Pennec A; Marianovski R; Pradier O; Bizais Y; Kraeber-Bodéré F; Salaun PY
    J Nucl Med; 2009 Jan; 50(1):24-9. PubMed ID: 19091901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FDG-PET/contrast-enhanced CT as a post-treatment tool in head and neck squamous cell carcinoma: comparison with FDG-PET/non-contrast-enhanced CT and contrast-enhanced CT.
    Suenaga Y; Kitajima K; Ishihara T; Sasaki R; Otsuki N; Nibu K; Minamikawa T; Kiyota N; Sugimura K
    Eur Radiol; 2016 Apr; 26(4):1018-30. PubMed ID: 26188656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Volumetric comparison of positron emission tomography/computed tomography using 4'-[methyl-¹¹C]-thiothymidine with 2-deoxy-2-¹⁸F-fluoro-D-glucose in patients with advanced head and neck squamous cell carcinoma.
    Ito K; Yokoyama J; Miyata Y; Toyohara J; Okasaki M; Minamimoto R; Morooka M; Ishiwata K; Kubota K
    Nucl Med Commun; 2015 Mar; 36(3):219-25. PubMed ID: 25369751
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of
    Piccardo A; Trimboli P; Puntoni M; Foppiani L; Treglia G; Naseri M; Bottoni GL; Massollo M; Sola S; Ferrarazzo G; Bruzzone M; Catrambone U; Arlandini A; Paone G; Ceriani L; Cabria M; Giovanella L
    Thyroid; 2019 Apr; 29(4):549-556. PubMed ID: 30864903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of Diffusion-Weighted Imaging and
    Noij DP; Martens RM; Koopman T; Hoekstra OS; Comans EFI; Zwezerijnen B; de Bree R; de Graaf P; Castelijns JA
    Clin Oncol (R Coll Radiol); 2018 Dec; 30(12):780-792. PubMed ID: 30318343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimal timing of post-treatment [18F]fluorodeoxyglucose-PET/CT for patients with head and neck malignancy.
    Nakamura S; Toriihara A; Okochi K; Watanabe H; Shibuya H; Kurabayashi T
    Nucl Med Commun; 2013 Feb; 34(2):162-7. PubMed ID: 23196675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Change of maximum standardized uptake value slope in dynamic triphasic [18F]-fluorodeoxyglucose positron emission tomography/computed tomography distinguishes malignancy from postradiation inflammation in head-and-neck squamous cell carcinoma: a prospective trial.
    Anderson CM; Chang T; Graham MM; Marquardt MD; Button A; Smith BJ; Menda Y; Sun W; Pagedar NA; Buatti JM
    Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):472-9. PubMed ID: 25680593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Positron emission tomographic imaging with 11C-choline in differential diagnosis of head and neck tumors: comparison with 18F-FDG PET.
    Khan N; Oriuchi N; Ninomiya H; Higuchi T; Kamada H; Endo K
    Ann Nucl Med; 2004 Jul; 18(5):409-17. PubMed ID: 15462403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preliminary study of 11C-choline PET/CT for T staging of locally advanced nasopharyngeal carcinoma: comparison with 18F-FDG PET/CT.
    Wu HB; Wang QS; Wang MF; Zhen X; Zhou WL; Li HS
    J Nucl Med; 2011 Mar; 52(3):341-6. PubMed ID: 21321282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective risk-adjusted [18F]Fluorodeoxyglucose positron emission tomography and computed tomography assessment of radiation response in head and neck cancer.
    Moeller BJ; Rana V; Cannon BA; Williams MD; Sturgis EM; Ginsberg LE; Macapinlac HA; Lee JJ; Ang KK; Chao KS; Chronowski GM; Frank SJ; Morrison WH; Rosenthal DI; Weber RS; Garden AS; Lippman SM; Schwartz DL
    J Clin Oncol; 2009 May; 27(15):2509-15. PubMed ID: 19332725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of post-treatment (18)F-FDG PET/CT for advanced head and neck cancer after combined intra-arterial chemotherapy and radiotherapy.
    Ito K; Shimoji K; Miyata Y; Kamiya K; Minamimoto R; Kubota K; Okasaki M; Morooka M; Yokoyama J
    Chin J Cancer Res; 2014 Feb; 26(1):30-7. PubMed ID: 24653624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer.
    Chang HT; Hu C; Chiu YL; Peng NJ; Liu RS
    PLoS One; 2014; 9(12):e115127. PubMed ID: 25517451
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Kim SA; Roh JL; Kim JS; Lee JH; Lee SH; Choi SH; Nam SY; Kim SY
    Eur J Cancer; 2017 Feb; 72():62-70. PubMed ID: 28027517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can (18)F-FDG PET/CT reliably assess response to primary treatment of head and neck cancer?
    Ul-Hassan F; Simo R; Guerrero-Urbano T; Oakley R; Jeannon JP; Cook GJ
    Clin Nucl Med; 2013 Apr; 38(4):263-5. PubMed ID: 23429398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. (18)F-FDG PET/CT surveillance at 3-6 and 12 months for detection of recurrence and second primary cancer in patients with head and neck squamous cell carcinoma.
    Kim JW; Roh JL; Kim JS; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
    Br J Cancer; 2013 Dec; 109(12):2973-9. PubMed ID: 24149172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.